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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable common childhood-onset neurodevelopmental
disorder. Some rare copy number variations (CNVs) affect multiple neurodevelopmental disorders such as intellectual
disability, autism spectrum disorders (ASD), schizophrenia and ADHD. The aim of this study is to determine to what
extent ADHD shares high risk CNV alleles with schizophrenia and ASD. We compiled 19 neuropsychiatric CNVs and test
14, with sufficient power, for association with ADHD in Icelandic and Norwegian samples. Eight associate with ADHD;
deletions at 2p16.3 (NRXN1), 15q11.2, 15q13.3 (BP4 & BP4.5–BP5) and 22q11.21, and duplications at 1q21.1 distal,
16p11.2 proximal, 16p13.11 and 22q11.21. Six of the CNVs have not been associated with ADHD before. As a group,
the 19 CNVs associate with ADHD (OR= 2.43, P= 1.6 × 10−21), even when comorbid ASD and schizophrenia are
excluded from the sample. These results highlight the pleiotropic effect of the neuropsychiatric CNVs and add
evidence for ADHD, ASD and schizophrenia being related neurodevelopmental disorders rather than distinct entities.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common childhood-onset neurodevelopmental disorder
characterized by a triad of signs—age-inappropriate levels of
inattentive, hyperactive and impulsive behavior—that lead
to severe impairments1. ADHD is estimated to affect 3.4%
of the population worldwide2. Follow-up studies of children
have documented the persistence of ADHD symptoms into
adulthood in approximately two-thirds of patients3.
Studies have focused on the relationship between
ADHD and schizophrenia4 in light of considerable over-
lap in clinical presentation and because ADHD is diag-
nosed in a high proportion of children at genetic risk of
schizophrenia5. Also, a schizophrenia polygenic score,
estimated from an adult population, was found to confer a
small but significant risk of childhood ADHD6. A history
of ADHD signs is common in individuals who develop
schizophrenia, with attentional impairment as a central
cognitive feature of both disorders4. Deficits in working
memory, cognitive flexibility and attention seen in ADHD
are similar to those observed in schizophrenia7. Likewise
family-based and twin studies in clinical ADHD samples
have shown that signs of autism spectrum disorders
(ASD) are common within ADHD families and that more
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than half of the phenotypic variance in either disorder
may be attributable to shared genetic factors8. This is
further supported by analyses showing that some
sequence variants confer risk of both ADHD and ASD9,10
and the two disorders share considerable common variant
genetic overlap11.
Heritability estimates suggest that ~74% of the pheno-
typic variability in ADHD is due to variants in the
sequence of the germline genome12. Genome-wide asso-
ciation studies (GWAS) have only recently reached sam-
ple sizes with adequate power to yield variants
significantly associated with ADHD13. The genome-wide
single-nucleotide polymorphism (SNP) heritability of
ADHD has been estimated at 22%, corresponding to the
contribution of common SNPs to ADHD susceptibility13.
This is lower than the heritability estimated from twin
studies and suggests that rare variants may also contribute
to the risk of ADHD14.
Rare copy number variations (CNVs) have been asso-
ciated with cognitive deficits that can result in dis-
advantages in educational attainment and various adult
life outcomes but more directly with increased risk of
psychiatric and developmental disorders, including schi-
zophrenia, ADHD, ASD and developmental delay15–20.
Evidence for increased burden of large, rare CNVs in
ADHD have been reported, suggesting CNVs contribute
to the disorder21–25. Two CNVs have previously been
associated with ADHD, 16p13.11 duplications23 and
22q11.21 deletions23,26. Furthermore, ADHD has been
reported in individuals with 1q21.1 distal deletions23 or
duplications27, 15q11.2 deletions28, 15q13.3 deletions29,30
and 16p11.2 proximal deletions31 or duplications32, but
have not been statistically tested for association.
While much of the current knowledge on the effects of
CNVs and associated risk comes from schizophrenia and
ASD samples, the aim of this study was to determine to
what extent rare CNVs, previously associated with schi-
zophrenia and/or ASD, associate with ADHD in a com-




This study was approved by the National Bioethics
Committee of Iceland. All individuals signed an informed
consent prior to giving a blood or buccal sample. Social
security numbers of participants were encrypted through
a process overseen by the Data Protection Authority
before being analyzed33.
The ADHD affected (total N= 5650) were included on
the basis of meeting criteria for ADHD diagnosis, any
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) and International Classification of Diseases
(ICD-9 or −10)-based subtype (N= 2665, male N= 1746)
or on confirmed information on treatment with ADHD
medication according to the Directorate of Health cen-
tralized medication database (N= 2985, male N= 1489)
(Supplementary Table 1).
Participants were diagnosed by a psychiatrist or pedia-
trician, in settings of collaborating centers, the University
hospital, the Centre for Child Development and Behavior,
the SLF’s Rehabilitation Center and private practice
clinics with diagnoses made on the basis of standardized
diagnostic assessments, reviewed by experienced clin-
icians, as part of their diagnostic and treatment regimen
in the national healthcare service, and not specifically for
this study.
The participants identified in the Directorate of Health
medication database have all been prescribed medication
from the centrally acting sympathomimetic (N06BA) class
of drugs (amphetamine (01), methylphenidate (04) or
atomoxetine (09)), based on the Anatomical Therapeutic
Chemical (ATC) Classification System. However, as
diagnoses are not registered in the medication database,
information on the ADHD status was not available for
these individuals. Although, amphetamine can be pre-
scribed for signs and symptoms other than ADHD, indi-
viduals prescribed amphetamine make up only 1% of the
entire ADHD medication sample and none of them are
neuropsychiatric CNV carriers. As methylphenydate and
atomoxetine are exclusively prescribed for ADHD in
Iceland, we have assumed that the individuals that make
up this group have all sought treatment for the signs and
symptoms of ADHD.
While diagnosed male subjects are about twice as many
as diagnosed female subjects, the gender ratio is close to
1:1 within the group prescribed medication, and so overall
the male-to-female ratio among ADHD subjects is about
3:2. The control sample (N= 155,122, male N= 71,492)
was recruited through various projects at deCODE
genetics.
Norwegian samples
The Norwegian ADHD affected (N= 3233) were
obtained from the Norwegian Mother and Child cohort
study (Mor og Barn; MoBa)34,35, which includes children
(N= 1858 born between 1999 and 2009) and adults
(N= 941; ADHD affected adults who are not parents of
ADHD affected children), and from the Bergen adult
ADHD study (N= 434)36. Norwegian controls were chil-
dren (N= 8245) and adults (N= 19,316) from the MoBa
study, controls from the Bergen adult ADHD study (N=
355) and adult blood donors (N= 5071) (Supplementary
Table 1).
The MoBa study is a nationwide prospective
population-based pregnancy cohort that includes 114,500
children, born between 1999 to 2009, and their mothers
(fathers also available in the majority of cases). Blood
Gudmundsson et al. Translational Psychiatry           (2019) 9:258 Page 2 of 9
samples were collected from both parents during preg-
nancy, and from the umbilical cord for the children after
birth. For a more detailed description of the sample see
Magnus et al.34,35. Written informed consent was
obtained from all mothers and fathers participating in the
study, and the Regional Comittee for Medical Research
Ethics (REC) as well as the Norwegian Data Inspectorate
approved the MoBa study. For this specific study, a
separate REC approval has been obtained. The MoBa data
has been linked to the Patient registry to identify ADHD
cases. All data have been deidentified prior to analyses.
The Bergen adult ADHD sample consists of participants
recruited through a Norwegian national medical registry
and by psychologists and psychiatrists at out-patient
clinics. ADHD diagnosis was defined according to DSM-
IV criteria as described elsewhere36. Random controls
were recruited through the Norwegian Medical Birth
registry. All participants provided either blood or saliva
samples for DNA extraction. All participants provided
signed informed consent. The study was approved by the
Norwegian regional medical research ethics committee
West (IRB #3 FWA00009490, IRB00001872).
The Norwegian Blood donors (Oslo University Hospital,
Ullevål Hospital, between 18 and 60 years) were included
in the control sample. They were all thoroughly screened
for diseases, and provided blood for DNA analysis, in line
with approval from the Regional Committee for Medical
and Health Research Ethics.
Neuropsychiatric CNV identification and calling
Nineteen CNVs conferring risk of schizophrenia or
ASD (‘neuropsychiatric CNVs’) were selected based on
recent publications17–19,37,38,39 (Supplementary Table 2).
Icelandic subjects carrying neuropsychiatric CNVs were
identified from a large genotyped sample (N= 160,772).
The samples were genotyped using the Illumina
HumanHap (300, 370, 610, 1M, 2.5M) and IlluminaOmni
(670, 1M, 2.5M, Express) SNP arrays. Norwegian neu-
ropsychiatric CNV carriers were identified from
36,220 samples genotyped on Illumina SNP arrays
(OmniExpress or Global Screening Array).
Genomestudio (Illumina; version v2011.1) was used to
call genotypes, normalize signal intensity data and estab-
lish the log R ratio (LRR) and B allele frequency (BAF) for
every SNP. PennCNV40 was then used to predict CNVs
from the SNP array data. Samples with LRR standard
deviation over 0.3 or BAF drift over 0.01 were discarded
from the analyses. The putative neuropsychiatric CNVs of
all samples were confirmed by visual inspection of LRR
and BAF plots over each predicted CNV region.
CNV association
The CNVs under investigation are rare, and in order to
estimate the minimum population frequency required to
have 80% power to detect an association with an OR of
above 3.9, we used the effect size calculation in the chi-
squared test for association function (ES.w2) in the basic
functions for power analysis (pwr) package (version
1.2–2) in R; pwr.chisq.test, N= 163,409 (correction factor
(see below) adjusted, Icelandic and Norwegian samples),
degrees of freedom= 1, significance level= 0.05.
To evaluate whether the neuropsychiatric CNVs were
significantly enriched in our Icelandic and Norwegian
ADHD sample, the number of case-carriers, case-non-
carriers, control-carriers and control-noncarriers was
determined per CNV, and CNVs combined, for each
sample and an odds ratio (OR) and P value were esti-
mated using a Fisher exact test (fisher.test) in R. To
account for relatedness within the Icelandic and Nor-
wegian samples, the P values were adjusted with a cor-
rection factor (1.187 and 1.033, respectively) estimated
using the intercept from LD score regression41. Prior to
meta-analysis, the Icelandic and Norwegian ADHD
affected and control, carrier and non-carrier counts, were
adjusted with the above correction factors, rounded to
the nearest integer, and then combined using the
Cochran–Mantel–Haenszel χ2 test for count data (man-
telhaen.test) in R. We used RStudio (version 1.0.44;
https://www.rstudio.com/) integrating R (version 3.3.2;
https://www.r-project.org/) and employing the stats base
package for the association tests and ggplot2 (version
2.2.1) to generate the power figure.
Results
Here we meta-analyze ADHD data from Iceland and
Norway (N= 8883 ADHD affected) (Methods and Sup-
plementary Table 1). The Icelandic sample combines two
ADHD study groups, a group of subjects diagnosed with
ADHD and a group of subjects assumed to have ADHD
based on prescription of ADHD medication. The subjects
diagnosed with ADHD are on average 13.6 years younger
than those prescribed medication for ADHD (mean age
30.3 and 43.9, respectively), and the combined ADHD
sample has a male to female ratio of 3:2. The Norwegian
ADHD sample, with a male to female ratio of 2:1, were
from the Norwegian mother and child cohort study
(MoBa)34,35, which includes children and adults, and from
the Bergen adult ADHD study36.
We compiled a list of 19 neuropsychiatric CNVs that
have been shown to confer risk of schizophrenia and/or
ASD17–19,37,38,39 (Supplementary Table 2). All but the
2p16.3 deletions are recurrent and flanked by segmental
duplications (Supplementary Fig. 1). All samples were
genotyped using Illumina SNP arrays and the preselected
neuropsychiatric CNVs were identified using the
PennCNV algorithm and confirmed by visual inspection
and segregation in pedigrees (Methods). Individually these
CNVs are rare (0.0027–0.25% carrier frequency in the
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population), and we estimated that at 80% power a CNV
with a frequency of 0.018% or greater was required to
detect an association with an OR above 3.9 (Supplemen-
tary Fig. 2 and Methods). The individual associations were
therefore restricted to CNVs with a population frequency
of >0.018% in the combined Icelandic and Norwegian
sample; deletions at 1q21.1 distal, 2p16.3 (NRXN1),
15q11.2, 15q13.3 (break point (BP)4 & BP4.5–BP5),
16p11.2 distal, 16p11.2 proximal, 16p12.1, 17p12 and
22q11.21 and duplications at 1q21.1 distal, 16p11.2
proximal, 16p13.11, 17q12 and 22q11.21.
Of the 14 CNVs tested, the two previously associated
with ADHD23,26, 16p13.11 duplication and 22q11.21
deletion were replicated in the combined Icelandic and
Norwegian sample (OR (95% CI)= 2.12 (1.31, 3.27), P=
0.0035 and OR (95% CI)= 10.73 (4.66, 23.15), P= 1.8 ×
10−6, respectively; Cochran–Mantel–Haenszel χ2 test for
count data and false discovery rate (FDR) adjusted P
value); it should be noted that a part of the Icelandic
sample was included in the original 16p13.11 duplication
study23 (Fig. 1, Table 1 and Supplementary Table 3).
Previous reports have shown a higher frequency of
ADHD in carriers of six (deletions at 1q21.1 distal,
15q11.2, 15q13.3 (BP4 & BP4.5–BP5) and 16p11.2 prox-
imal and duplications at 1q21.1 distal and 16p11.2 prox-
imal) of the remaining 12 CNVs, although not statistically
tested27–29,32. We present evidence of significant asso-
ciation with ADHD for deletions at 15q11.2 and 15q13.3
(BP4 & BP4.5–BP5) and duplications at 1q21.1 distal and
16p11.2 proximal. The remaining six CNVs have not
been associated with a diagnosis of ADHD before; the
deletions at 2p16.3 (NRXN1), 16p11.2 distal, 16p12.1
and 17p12 and duplications at 17q12 and 22q11.21. Of
those, the 2p16.3 (NRXN1) deletion and 22q11.21
duplication were significant in the combined sample
(OR (95% CI)= 4.68 (1.82, 10.64), P= 0.0020 and OR
(95% CI)= 2.24 (1.32, 3.63), P= 0.0042, respectively;
Cochran–Mantel–Haenszel χ2 test for count data and
FDR adjusted P value) (Fig. 1, Table 1 and Supplemen-
tary Table 3). Affected and control, carrier frequency for
the five remaining, individually untested, CNVs are
given in Fig. 1 and Supplementary Table 4.
Combining the 19 neuropsychiatric CNVs, we per-
formed a Cochran–Mantel–Haenszel χ2 test for count
data on the Icelandic and Norwegian ADHD samples to
estimate the overall CNV burden. This revealed a sig-
nificant association with ADHD (OR (95% CI)= 2.43
(2.05, 2.87), P= 1.6 × 10−21; counts adjusted for correc-
tion factor, see Methods). The combined neuropsychia-
tric CNVs have a carrier frequency of 2.15% in the
Icelandic and Norwegian ADHD sample compared with
0.86% in the combined controls. The associations with
ADHD in the Icelandic and Norwegian samples, sepa-
rately, were similar (OR (95% CI)= 2.30 (1.86, 2.80), P=
1.4 × 10−11 and OR (95% CI)= 2.66 (2.04, 3.43), P=
7.7 × 10−12, respectively; Fisher’s exact test and corrected
P values) (Table 2).
Removing CNVs individually associated with ADHD
from the combined set, we found the remaining 11 CNVs
(deletions at 1q21.1 distal, 3q29, 16p11.2 distal, 16p11.2
proximal, 16p12.1, 17p12 and 17q12 and duplications at
7q11.23, 7q36.3, 15q11.2–13.1, 17q12) still conferred a
significant risk of ADHD (OR (95% CI)= 1.94 (1.33, 2.76),
P= 6.0 × 10−4; Cochran–Mantel–Haenszel χ2 test for
count data in the Icelandic and Norwegian sample counts
adjusted with correction factors and combined).
Although, this appears to be mostly accounted for by the
six, relatively, more common CNVs tested, as when they
are removed the OR is no longer significant for the five
remaining CNVs (OR (95% CI)= 1.38 (0.27, 4.42), P=
0.49; Cochran–Mantel–Haenszel χ2 test for count data in
the Icelandic and Norwegian sample counts adjusted with
correction factors and combined) (Table 2).
We also explored what effect removing individuals with
a diagnosis of ASD or schizophrenia, from the Icelandic
sample of ADHD affected and controls, would have on the
risk for ADHD conferred by the neuropsychiatric CNVs,
and found a modest weakening of the signifcance as
expected but a subtle increase in OR for nine out of 14
CNVs. However, the CNVs combined showed a similar,
although less significant, effect (OR (95% CI)= 2.26 (1.81,
2.79), P= 1.2 × 10−11; Fisher’s exact test) (Supplementary
Table 5).
For the Norwegian sample, the issue of ADHD
comorbid with axis I to III disorders was addressed in a
recent study where the authors found children with
ADHD in MoBa were registered with fewer abnormal
psychosocial situations (axis I disorders) compared with
children in the general population42. Within the Bergen
sample, none of the CNV carriers has a diagnosis of
schizophrenia and only one is comorbid ADHD and ASD.
It is, therefore, unlikely that the comorbid ASD or schi-
zophrenia are responsible for the risk conferred by the
neuropsychiatric CNVs present in the Norwegian sample.
We note that the OR for the neuropsychiatric CNVs
appears to be higher in the sample of Icelandic subjects
with an ADHD diagnosis than in the medication sample
(OR (95% CI)= 3.49 (2.72, 4.42), P= 1.6 × 10−17 and OR
(95% CI)= 1.25 (0.84, 1.79), P= 0.25, respectively; Fish-
er’s exact test and corrected P values. P value for differ-
ence= 2.4 × 10−5) (Supplementary Tables 6 and 7). A
corresponding analysis in the Norwegian sample reveals a
comparable, although nonsignificant (P= 0.10), trend
where the OR is higher in children with ADHD than in
adults with ADHD (OR (95% CI)= 2.69 (1.89, 3.78), P=
5.9 × 10−8 and OR (95% CI)= 1.56 (0.86, 2.63), P= 0.11,
respectively; Fisher’s exact test and corrected P value)
(Supplementary Tables 8 and 9).
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Discussion
The results of the current study, combining large
ADHD samples from relatively homogenous populations,
in terms of genetics and health care systems, support
previous findings of increased burden of rare CNVs
among ADHD patients23. The neuropsychiatric CNVs
confer a substantial risk of ADHD in the Icelandic and
Norwegian samples. As the CNVs are individually rare, we
estimated that 14 were powered to detect a significant
association. When we looked at carrier status of the
neuropsychiatric CNVs separately, eight were significantly
associated with ADHD risk after adjusting for FDR:
deletions at 2p16.3 (NRXN1), 15q11.2, 15q13.3 (BP4 &
BP4.5–BP5) and 22q11.21, and duplications at 1q21.1
distal, 16p11.2 proximal, 16p13.11 and 22q11.21. Two of
these CNVs have previously been associated with ADHD,
the 16p13.11 duplication and 22q11.21 deletion. Of the
remaining six, four have been previously reported with
higher frequency of ADHD in carriers but not statistically
tested and the deletion at 2p16.3 spanning exons of
NRXN1 and the 22q11.21 duplication have not been
associated with ADHD diagnosis before.
The CNV conferring the highest risk of ADHD in our
study is the deletion at 22q11.21. The 22q11.2 deletion
syndrome (DiGeorge Syndrome) is associated with high
rates of schizophrenia spectrum disorders and has been
exploited as a genetic model for understanding the
development of schizophrenia26. Of other psychiatric
conditions associated with the deletion, ADHD has been
shown to be the most frequent disorder in children (37%)
with the inattentive presentation persisting into
adulthood26.
The 16p13.11 duplication, which has been associated
with schizophrenia19 and ADHD23,43,44, also reached sig-
nificance threshold in this study, although it should be
noted that a part of the Icelandic sample was included in
the original Williams et al. study23.
The 1q21.1 distal CNV has been associated with mul-
tiple phenotypes27, including neurodevelopmental and
psychiatric disorders, deletions more strongly with
Fig. 1 Neuropsychiatric CNV association with ADHD in Icelandic and Norwegian samples. The affected and control carrier frequencies were
calculated from the combined number of CNV carriers divided by the number of genotyped individuals in the Icelandic and Norwegian sample
combined, before adjusting the counts for relatedness. For Icelandic and Norwegian population frequency separately, see Supplementary Table 3. To
estimate OR and P values, the Icelandic and Norwegian affected and control, carrier and non-carrier counts, were adjusted for relatedness with a
correction factor (1.187 in Iceland and 1.033 in Norway) using the intercept from LD score regression41, rounded to the nearest integer, and then
combined using the Cochran–Mantel–Haenszel χ2 test for count data. The P values were further adjusted by false discovery rate (FDR).
Neuropsychiatric CNVs below the horizontal, dashed, gray line were not tested as their population carrier frequency was below 0.018% (vertical,
dashed, gray line) required for the 80% power to detect CNVs with an OR 3.9
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schizophrenia19 and duplications with ASD17. An increase
in the frequency of ADHD among both 1q21.1 distal
deletion (5%) and duplication (29%) carriers has also been
reported27. While we confirm this observation with an
association of the 1q21.1 distal duplication with ADHD,
the 1q21.1 distal deletion is not significant.
The 15q11.2 deletion has been associated with schizo-
phrenia19 but also with learning difficulties and brain
structural changes20,45, as well as an increased frequency
of ADHD in carriers28. We see a modest association with
ADHD in the combined sample.
The 15q13.3 (BP4 & BP4.5–BP5) deletion has previously
been associated with mental retardation, seizures, dys-
morphic features and schizophrenia46. A review of
15q13.3 deletions, involving 246 cases with deletions
overlapping the 15q13.3 (BP4–BP5) region, found an
increased frequency of neuropsychiatric conditions,
including ADHD (6.5%)29. We see a highly significant
association with ADHD, marginally stronger in the Nor-
wegian sample.
The proximal duplication at 16p11.2 has been asso-
ciated with schizophrenia19 and ASD17 but also reported a
higher frequency (39–60%) of ADHD in carriers32,47. We
report a strong and highly significant association with
ADHD in our combined sample. 16p11.2 proximal
deletion, although not significantly associated with
ADHD, showed a definite reversal of OR after excluding
individuals with a diagnosis of ASD or schizophrenia from
the ADHD and controls samples.
Deletions spanning exons of NRXN1 have been identi-
fied in individuals diagnosed with a range of neurodeve-
lopmental disorders, including intellectual disability,
speech and language delay, ASD and schizophrenia48 but
to our knowledge not ADHD, apart from two clinical
referrals for diagnostic cytogenetic analysis49. We observe
a modest association between deletions removing NRXN1
exons at 2p16.3 and ADHD in our study.
Current understanding of the 22q11.21 duplication
clinical phenotype is quite diverse, but range from ASD17,
severe mental retardation, dysmorphic facial features and
heart malformations38 to no signs at all. Notably, while all
of the neuropsychiatric CNVs have been associated with
increased risk of either schizophrenia or ASD, it has been
postulated that the 22q11.21 duplication may confer pro-
tection against schizophrenia37,39,50. The 22q11.21 dupli-
cation has not been previously associated with ADHD in a
population sample, although a Danish nationwide CNV
registry study did find a modest increase in “any psychiatric
disorder” (including ADHD) diagnosis in 22q11.2 dupli-
cation carriers51. Furthermore, a prospective study of a
Table 1 Neuropsychiatric CNV association with ADHD in Icelandic and Norwegian samples
Neuropsychiatric CNV loci tested Iceland and Norway combined
Affected/control carrier frequency (%)a OR (95% CI), P (FDR adjusted)b
1q21.1 distal—deletion 0.0788/0.0288 2.68 (0.92, 6.44), 0.054
1q21.1 distal—duplication 0.146/0.0454 3.44 (1.67, 6.52), 0.0020
2p16.3 (NRXN1)—deletion 0.101/0.0210 4.68 (1.82, 10.64), 0.0026
15q11.2—deletion 0.417/0.244 1.65 (1.11, 2.37), 0.016
15q13.3 (BP4 & BP4.5–BP5) deletionc 0.135/0.0194 5.97 (2.63, 12.6), 1.0 × 10−4
16p11.2 distal—deletion 0.0338/0.0177 2.19 (0.42, 7.29), 0.19
16p11.2 proximal-deletion 0.0788/0.0354 2.16 (0.75, 5.11), 0.14
16p11.2 proximal—duplication 0.191/0.0437 4.34 (2.27, 7.81), 9.1 × 10−5
16p12.1—deletion 0.101/0.0664 1.52 (0.63, 3.16), 0.26
16p13.11—duplication 0.293/0.129 2.12 (1.31, 3.27), 0.0035
17p12—deletion 0.0563/0.0288 2.20 (0.67, 5.66), 0.13
17q12—duplication 0.0675/0.0315 2.20 (0.76, 5.24), 0.14
22q11.21—deletion 0.135/0.0155 10.73 (4.66, 23.15), 1.8 × 10−6
22q11.21—duplication 0.248/0.100 2.24 (1.32, 3.63), 0.0042
aThe affected and control carrier frequencies were calculated from the combined number of CNV carriers divided by the number of genotyped individuals in the
Icelandic and Norwegian sample combined, before adjusting the counts for relatedness. For Icelandic and Norwegian population frequency separately, see
Supplementary Table 3
bThe Icelandic and Norwegian affected and control, carrier and non-carrier counts, were adjusted for relatedness with a correction factor (1.187 in Iceland and 1.033 in
Norway) using the intercept from LD score regression41, rounded to the nearest integer, and then combined using the Cochran–Mantel–Haenszel χ2 test for count
data. The P values were further adjusted by false discovery rate (FDR)
cBP—break point
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cohort of children, found ADHD symptom scores to be
significantly higher in 22q11.2 duplication carriers in
comparison to typically developing children38. Only the
22q11.21 CNV has been shown to have a mirror effect on a
psychiatric disorder: The deletion confers risk of schizo-
phrenia26 whereas the reciprocal duplication has been
postulated to be protective against the same disorder37.
Interestingly, here we demonstrate that both alleles of the
22q11.2 CNV confer risk of ADHD.
Although only a subset of the neuropsychiatric CNVs
were predicted to provide well-powered estimates of
ADHD risk, all 19 combined were, unsurprisingly, highly
significantly associated with ADHD. To explore whether
any of the individually non-significant or untested CNVs
conferred some latent risk of ADHD, we combined them
in two seperate sets. While the slightly more common, but
individually non-significant, CNVs combined did reveal
an association with ADHD, the smaller set of very rare
CNVs combined were not significant. A larger sample of
carriers is required to ascertain whether those CNVs
associate with ADHD.
A potential confounder of analyses such as the one
presented here is the presence of ASD or schizophrenia
comorbid with ADHD and the risk conferred by the
neuropsychiatric CNVs being attributable to those con-
ditions. We reanalyzed the individual and combined
neuropsychiatric CNVs, after excluding individuals with a
diagnosis of ASD or schizophrenia in both the ADHD and
control samples and found only modest changes in the
risk estimates and as expected some change in the P
values. However, the overall conclusion is that these
CNVs, individually or combined, confer risk of ADHD
with or without ASD or schizophrenia.
As noted, neuropsychiatric CNVs appear to confer
greater risk of ADHD in individuals with a diagnosis
compared with those prescribed medication for ADHD.
The sample with a diagnosis is younger than those on
medication and so rather than an actual difference in risk
between the two groups this, more likely, reflects a more
complete recruitment for the younger sample and so a
broader spectrum of ADHD risk variants are represented
whereas high risk CNVs are likely to be underrepresented
in the older medication sample. With the proviso that
diagnostic criteria and clinical practice are stable over
time, it is likely that if individuals born prior to the
commencement of systematic ADHD screening and
diagnosis would be better represented in ADHD study
samples, an increase in CNV frequency would also be
observed.
In this study, we show that neuropsychiatric CNVs,
previously associated with schizophrenia and ASD, also
confer risk of ADHD. Hence, further emphasizing the
pleiotropic effects of CNVs. This adds to the evidence that
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distinct entities and supports previous findings of both
common and rare variant sharing. While, a unifying factor
of the neuropsychiatric CNVs is their negative impact on
cognitive abilities and disadvantages in educational
attainment that potentially explain part of their associa-
tion with psychiatric disorders, environmental interac-
tions and other sequence variants in CNV carriers may
affect the disorder expressed.
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